S6.12.1 - After the Semaglutide Approval: Impact on Patients and Pharmacotherapy

Send us a text Patient advocates discuss how doctors and other providers can serve patient needs better Guest surfer Anthony Villiotti, President of NASH kNOWledge, Inc. joins the Surfers. Tony and Surfer Donna Cryer, President & CEO of Global Liver Institute, discuss the way that better delivery of disease information and care can keep patients healthier longer and make them more knowledgeable about their disease. Too often patients are told not to worry about a fatty liver until the da...

13 Aug 20201h 1min

Send us a text Donna Cryer, President & CEO of the Global Liver Institute, and Louise Campbell, Founder of Tawazun Health, become Surfing regulars in an episode focused on the pivotal papers at EASL's Digital ILC meeting August 27-29. The group discusses the section addressing COVID-19 and liver disease links along with presentations and posters discussing use of FibroScan, AI-aided test analysis, reducing cardiovascular risk by treating NAFLD and evaluating liver fibrosis in diabetes wor...

6 Aug 202050min

Send us a text The Surfers focus on steps Allied Health Professions and passionate physicians can take to improve lifestyle compliance with #NASH and #NAFLD therapies. The group explores whether the healthcare system can be as effective as companies like Noom and WeightWatchers. This week's Music from the Liver Community: beautiful Oud music from Dr. Naim Alkhouri.

30 Juli 202044min

Send us a text FOCUS: Some of the presentations that will make NASH/NAFLD news next month Transplant hepatologist Naim Alkhouri joins the Surfers in discussing a dozen intriguing paper or session titles listed as part of the scientific program at next month’s Digital International Liver Congress. The discussion touches briefly on SurfingNASH’s plans for expanded Digital ILC coverage and even features a two-minute blues song from pharmaceutical economist and chart-busting blues artist Michissi...

23 Juli 202047min

Send us a text NASH is not merely a byproduct of obesity. The role the liver plays in non-liver comorbidities is complex and important. Join the Surfers as they give the liver the respect it’s due. “The ways liver affects outcomes is a very, very complex topic which, for the sake of argument, is sometimes simplified down to obesity…but like our perspective on NASH demonstrates, there's a lot going on.” – Suneil Hosmane Browse Our NASH and COVID-19 Coverage https://surfingnash.com/covi...

16 Juli 202052min

Send us a text FOCUS: Three sets of tools that will improve NASH disease understanding. The Surfers return to diagnostics once more. This time, they explore the utility of novel blood and serum tests, assess the benefits of smaller imaging devices and consider the impact that artificial intelligence and machine learning can have in improving how we diagnose and what we learn from biopsies…one more piece of an exciting future for Fatty Liver stakeholders. #NASH #NAFLD #FattyLiverDisease

9 Juli 20201h 13min

Send us a text Decoding the message of Intercept’s Complete Response Letter Former FDA Director Brian Harvey joins the Surfers to discuss what obeticholic acid’s rejection might mean for other NASH medicines in development. Is this the end of accelerated approvals? Does it simply mean we need better drugs? Join the debate

2 Juli 202053min

Send us a text CONSENSUS: the big story will be the regrowth of COVID-19 in the US and its implications. The Surfers discuss different elements of the evolving COVID-19 story — what it feels like to live in an emerging “hotspot” city, new findings on the impact Fatty Liver Disease may have on disease severity, and the commercial implications of all this. #NASH #NAFLD #FattyLiverDisease # COVID #COVID19 Browse Our NASH and COVID-19 Coverage https://surfingnash.com/covid-19/

27 Juni 202053min